鹿得医疗(832278) - 2023 Q1 - 季度财报

Financial Performance - Net profit attributable to shareholders for Q1 2023 was CNY 12.30 million, representing a significant increase of 48.39% year-over-year[11]. - Operating revenue for the first quarter of 2023 was CNY 79.58 million, up 4.35% from CNY 76.26 million in the same period last year[11]. - The net cash flow from operating activities improved to CNY 20.01 million, a 173.66% increase compared to a net outflow of CNY 27.17 million in the previous year[11]. - Total revenue for Q1 2023 reached ¥79,581,657.02, an increase of 4.3% compared to ¥76,264,998.06 in Q1 2022[39]. - Net profit for Q1 2023 was ¥12,301,975.66, representing a significant increase of 60.5% from ¥7,695,420.23 in Q1 2022[41]. - Operating profit for Q1 2023 was ¥12,104,156.29, a significant increase of 187.5% compared to ¥4,203,364.57 in Q1 2022[45]. - The total comprehensive income for Q1 2023 was ¥11,015,825.86, reflecting a substantial increase from ¥3,642,258.77 in Q1 2022[45]. Assets and Liabilities - Total assets as of March 31, 2023, reached CNY 495.70 million, an increase of 2.72% compared to the end of 2022[11]. - The company's asset-liability ratio (consolidated) decreased to 18.97% from 19.31% at the end of 2022[11]. - The total liabilities of the company stood at CNY 94,011,706.94 as of March 31, 2023, compared to CNY 93,170,485.25 at the end of 2022, showing a slight increase of about 0.9%[33]. - The company's total equity increased to CNY 401,692,409.08 as of March 31, 2023, from CNY 389,390,433.42 at the end of 2022, marking an increase of approximately 3.2%[33]. - The company's total assets as of March 31, 2023, amounted to ¥465,562,155.65, compared to ¥456,349,751.20 at the end of 2022, indicating a growth of 2.6%[37]. - The company's total liabilities decreased to ¥76,173,185.29 from ¥77,976,606.70, a reduction of 2.3%[37]. Cash Flow - Cash flow from operating activities for Q1 2023 was ¥20,011,563.46, a turnaround from a negative cash flow of ¥27,166,252.58 in Q1 2022[46]. - Cash and cash equivalents at the end of Q1 2023 totaled ¥193,307,419.41, compared to ¥177,993,134.27 at the end of Q1 2022[48]. - The net increase in cash and cash equivalents was $7.85 million, a recovery from a decrease of $22.78 million in the previous period[50]. - The ending balance of cash and cash equivalents was $171.33 million, up from $163.48 million at the beginning of the period, indicating improved liquidity[50]. Shareholder Information - The total number of shares outstanding is 176,000,000, with 41.47% being unrestricted shares held by controlling shareholders[18]. - The top five shareholders collectively hold 71.61% of the total shares, with the largest shareholder, Xiang Youliang, owning 22.23%[21]. - The company has 7,227 common shareholders as of the end of the reporting period[18]. - There were no changes in the number of restricted shares during the reporting period, remaining at 103,011,600, which constitutes 58.53% of total shares[18]. Expenses - Sales expenses for Q1 2023 were CNY 4.54 million, up 32.93% year-over-year, driven by increased export sales and marketing efforts[15]. - Research and development expenses for Q1 2023 were ¥2,179,698.65, a decrease of 25.7% from ¥2,934,807.32 in Q1 2022[41]. - Sales expenses increased to ¥2,942,959.74 in Q1 2023, up 91.1% from ¥1,540,836.65 in Q1 2022[44]. Legal and Compliance - The company reported no significant litigation or arbitration matters that would impact its financial position[25]. - The company has complied with all internal review procedures for significant matters during the reporting period[24]. - The company has not engaged in any share buyback activities during the reporting period[24]. - The company has fulfilled all previously disclosed commitments in a timely manner[24]. - The company is currently involved in a legal dispute with Sunshine Property Insurance Co., Ltd., with a claim for compensation amounting to CNY 1,137,045.59[26]. Investments - Investment income surged by 765.72% to CNY 2.79 million, attributed to strong performance from associated enterprises[15]. - The company has projected a total of CNY 10,700,000 for related party transactions in 2023, with actual transactions in the first quarter amounting to CNY 2,572,949, which is about 24% of the projected total[29]. - Non-recurring gains and losses for the period totaled CNY 249.82 million, with a net amount of CNY 222.30 million after tax impacts[16].